Lipid biology of the podocyte--new perspectives offer new opportunities.
about
Obesity-Related Chronic Kidney Disease-The Role of Lipid MetabolismPathophysiology of Non Alcoholic Fatty Liver DiseaseTRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseasesIdentification and biochemical characterization of an acid sphingomyelinase-like protein from the bacterial plant pathogen Ralstonia solanacearum that hydrolyzes ATP to AMP but not sphingomyelin to ceramideLipoprotein X Causes Renal Disease in LCAT DeficiencyCombined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension TrialExpression of uPAR in Urinary Podocytes of Patients with Fabry Disease.Apolipoprotein L1, income and early kidney damage.APOL1 G1 genotype modifies the association between HDLC and kidney function in African AmericansRenal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in PodocytesExamination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease.Distinct urinary lipid profile in children with focal segmental glomerulosclerosisSystemic and renal lipids in kidney disease development and progression.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDLThe glomerular permeability factors in idiopathic nephrotic syndrome.Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts.Podocyte Purinergic P2X4 Channels Are Mechanotransducers That Mediate Cytoskeletal Disorganization.Lipotoxicity as a trigger factor of renal disease.Angiotensin II induces cholesterol accumulation and injury in podocytes.Nutritional regulation of renal lipogenic factor expression in mice: comparison to regulation in the liver and skeletal muscle.Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.A kidney-specific genome-scale metabolic network model for analyzing focal segmental glomerulosclerosis.Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.APOL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase 2.Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia
P2860
Q26774143-B9DD078B-DF73-4537-A98F-4A53660418E3Q28070011-BC8F73EA-E8CD-4218-B6D8-BE2E0A83CAF4Q28081895-88F1BFDF-B13C-474D-AE65-2AAEEEAFE05DQ28542500-51924B9D-02DD-42BD-B9E9-7C9F45C67BA1Q28550403-7A1523CB-10A6-4DAA-B63D-BF907E095B50Q30277219-7280BFBA-793C-40B4-A2DC-DC5B6268200AQ33646324-38319261-792C-4F7F-B92E-CC70C082A5F0Q35180863-B18B00CC-8B4C-49EA-B4FD-C597521178DAQ35646631-57150A7B-127E-41B1-A5AB-6F12F0EE8E31Q35834459-97854927-B04F-4DB4-9E65-39CBAC93ACA7Q36349456-6DD786BB-3657-4BAF-B3F8-7EC92C24B3E2Q36389638-8D5DC601-D1BF-434F-8C38-C16179F86E88Q37130343-4D402986-8B3D-4865-A8D4-849D0089A026Q37148885-E05EFF52-6BFE-48F5-B277-B6BD6E19919FQ37217446-EF8BFC70-901B-4CD5-836C-A0CF5CF75F0CQ37662913-F30F202B-6B73-487C-B7F8-9692D7730F8DQ38449629-F52653EC-6E73-44A9-B22B-486E271008EDQ38619068-077CAFD0-CEF0-455D-91E5-35A0B012FA06Q38653995-5B5E9219-171C-4E5E-8ECA-263EB3DD282EQ38765934-5B703FE5-1E6B-45A1-B32D-19C24BEC3CB5Q41637033-BCD0AA3D-18E1-4D89-8C96-F317707550C7Q47341237-EC6DCBDE-99DC-4A7A-82DB-9D112CC03F49Q47363893-E1744817-E14A-405C-85B4-3F82FF410514Q50703084-E05A296B-54C9-4734-8A34-16A5D8ABD77AQ51328717-4456DB22-FB18-4AB4-A9D7-5150623823A5Q51736940-4DFDF0D4-63B3-40C2-9EEE-81F3372A7F90Q51751256-A21190BF-8992-4BD2-8DAE-3CAC374BE0A4Q52708939-851E7D8F-9220-45C5-944C-0EE7CEFAA2F3Q53637511-A4433D4D-83F6-4692-B5EB-16F828FF20A1Q57147536-D72E9E31-D849-4C18-8A35-61DF54B62A53
P2860
Lipid biology of the podocyte--new perspectives offer new opportunities.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lipid biology of the podocyte--new perspectives offer new opportunities.
@ast
Lipid biology of the podocyte--new perspectives offer new opportunities.
@en
type
label
Lipid biology of the podocyte--new perspectives offer new opportunities.
@ast
Lipid biology of the podocyte--new perspectives offer new opportunities.
@en
prefLabel
Lipid biology of the podocyte--new perspectives offer new opportunities.
@ast
Lipid biology of the podocyte--new perspectives offer new opportunities.
@en
P2860
P356
P1476
Lipid biology of the podocyte--new perspectives offer new opportunities.
@en
P2093
Alessia Fornoni
P2860
P2888
P304
P356
10.1038/NRNEPH.2014.87
P407
P577
2014-05-27T00:00:00Z
P6179
1048421190